Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Price Down 8% – Here’s What Happened

Posted by Brenda Bartman on Jul 8th, 2026

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report)’s stock price traded down 8% on Wednesday . The company traded as low as $27.44 and last traded at $27.59. Approximately 256,776 shares traded hands during trading, a decline of 32% from the average daily volume of 375,752 shares. The stock had previously closed at $30.00.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Evercore began coverage on Damora Therapeutics, Inc. Common Stock in a research report on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 price objective on the stock. HC Wainwright assumed coverage on Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 11th. They issued a “buy” rating and a $45.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. TD Cowen started coverage on Damora Therapeutics, Inc. Common Stock in a research report on Monday, June 8th. They issued a “buy” rating for the company. Finally, Royal Bank Of Canada assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Friday, April 24th. They issued an “outperform” rating and a $40.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $42.43.

Check Out Our Latest Report on DMRA

Damora Therapeutics, Inc. Common Stock Trading Down 7.4%

The firm has a market capitalization of $1.71 billion, a PE ratio of -4.98 and a beta of 1.46. The business’s 50 day simple moving average is $24.07 and its 200 day simple moving average is $25.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). Analysts forecast that Damora Therapeutics, Inc. Common Stock will post -1.92 earnings per share for the current year.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Several institutional investors have recently added to or reduced their stakes in the company. Ikarian Capital LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at approximately $6,574,000. Jain Global LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at approximately $2,774,000. Remedium Capital Partners LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at approximately $2,772,000. Boothbay Fund Management LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter worth approximately $2,204,000. Finally, Connective Capital Management LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock in the third quarter valued at about $100,000. Institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

(Get Free Report)

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.